Ideas to Impact
Absci is unlocking the potential of next-generation biologics by harnessing deep learning AI and synthetic biology to explore a vast therapeutic sequence space inaccessible to conventional discovery methods.
We started with a question: What if there was a better way to create new medicines?
From a basement in Portland, we engineered E. coli, biopharma’s original host organism, to be an effective factory for complex human proteins. But we didn’t stop there.
We built our technology to enable better, faster, smarter biologic drug discovery and cell line development. We call it Integrated Drug Creation™.
Get to know us.
Absci is unlocking the potential of next-generation biologics by harnessing deep learning AI and synthetic biology to explore a vast therapeutic sequence space inaccessible to conventional discovery methods.
Sean McClain
Founder, CEO & Director
Matthew Weinstock, PhD
CTO
Greg Schiffman, CPA
CFO
Sarah Korman, PhD, JD
General Counsel
Nikhil Goel, MS, MBA
Chief Strategy Officer
Penelope
Chief Morale Officer
Deniz Kural, PhD
SVP, Antibody & Target Discovery
James Sietstra
SVP, Business Development
Imad Ajjawi, PhD, MBA
VP, Business Development
Todd Bedrick, CPA
VP, Corporate Controller
Kate Corcoran, PhD
VP, Strategy & Communication
Jonathan Eads, MS
VP, Informatics
Gregory Hannum, PhD
VP, AI Research
Byron Kneller, PhD
VP, Process Development
Jens Plassmeier, PhD
VP, Synthetic Biology R&D
Thomas Wrona, PhD, JD
VP, Intellectual Property
Daniele Biasci, PhD
Consulting VP, Immunology
Explore current openings and get ready to prove that impossible isn’t.
Join us